Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas
- PMID: 26336885
- DOI: 10.1038/modpathol.2015.96
Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas
Abstract
HMGA2, CDK4, and JUN genes have been described as frequently coamplified with MDM2 in atypical lipomatous tumor, well-differentiated liposarcoma, and dedifferentiated liposarcoma. We studied the frequency of amplification of these genes in a series of 48 dedifferentiated liposarcomas and 68 atypical lipomatous tumors/well-differentiated liposarcomas. We correlated their amplification status with clinicopathological features and outcomes. Histologically, both CDK4 (P=0.007) and JUN (P=0.005) amplifications were associated with dedifferentiated liposarcoma, whereas amplification of the proximal parts of HMGA2 (5'-untranslated region (UTR) and exons 1-3) was associated with atypical lipomatous tumor/well-differentiated liposarcoma (P=0.01). CDK4 amplification was associated with axial tumors. Amplification of 5'-UTR and exons 1-3 of HMGA2 was associated with primary status and grade 1. Shorter overall survival was correlated with: age >64 years (P=0.03), chemotherapy used in first intent (P<0.001), no surgery (P=0.003), grade 3 (P<0.001), distant metastasis (P<0.001), node involvement (P=0.006), and CDK4 amplification (P=0.07). In multivariate analysis, distant metastasis (HR=8.8) and grade 3 (HR=18.2) were associated with shorter overall survival. A shorter recurrence-free survival was associated with dedifferentiated liposarcoma (P<0.001), grade 3 (P<0.001), node involvement (P<0.001), distant metastasis (P=0.02), recurrent status (P=0.009), axial location (P=0.001), and with molecular features such as CDK4 (P=0.05) and JUN amplification (P=0.07). Amplification of 5'-UTR and exons 1-3 (P=0.08) and 3'-UTR (P=0.01) of HMGA2 were associated with longer recurrence-free survival. Distant metastasis was associated with shorter recurrence-free survival (HR=5.8) in multivariate analysis. Dedifferentiated liposarcoma type was associated with axial location, grade 3 and recurrent status. In conclusion, we showed that the amplification of HMGA2 was associated with the atypical lipomatous tumor/well-differentiated liposarcoma histological type and a good prognosis, whereas CDK4 and JUN amplifications were associated with dedifferentiated liposarcoma histology and a bad prognosis. In addition, we also provided the first description of the molecular evolution of a well-differentiated liposarcoma into four successive dedifferentiated liposarcoma relapses, which was consistent with our general observations.
Similar articles
-
Detection of MDM2/CDK4 amplification in lipomatous soft tissue tumors from formalin-fixed, paraffin-embedded tissue: comparison of multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situ hybridization (FISH).Appl Immunohistochem Mol Morphol. 2015 Feb;23(2):126-33. doi: 10.1097/PDM.0000000000000041. Appl Immunohistochem Mol Morphol. 2015. PMID: 25679065
-
High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma.Histol Histopathol. 2014 Jan;29(1):127-38. doi: 10.14670/HH-29.127. Epub 2013 Jul 15. Histol Histopathol. 2014. PMID: 23852861
-
HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.Int J Cancer. 2008 May 15;122(10):2233-41. doi: 10.1002/ijc.23380. Int J Cancer. 2008. PMID: 18214854
-
Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review.Crit Rev Oncol Hematol. 2020 Sep;153:103029. doi: 10.1016/j.critrevonc.2020.103029. Epub 2020 Jun 18. Crit Rev Oncol Hematol. 2020. PMID: 32593094 Review.
-
Well-differentiated and dedifferentiated liposarcomas.Virchows Arch. 2010 Feb;456(2):167-79. doi: 10.1007/s00428-009-0815-x. Epub 2009 Aug 18. Virchows Arch. 2010. PMID: 19688222 Review.
Cited by
-
Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.Onco Targets Ther. 2016 Oct 11;9:6233-6246. doi: 10.2147/OTT.S112580. eCollection 2016. Onco Targets Ther. 2016. PMID: 27785071 Free PMC article. Review.
-
Liposarcoma: Advances in Cellular and Molecular Genetics Alterations and Corresponding Clinical Treatment.J Cancer. 2020 Jan 1;11(1):100-107. doi: 10.7150/jca.36380. eCollection 2020. J Cancer. 2020. PMID: 31892977 Free PMC article. Review.
-
Integrated exome and RNA sequencing of dedifferentiated liposarcoma.Nat Commun. 2019 Dec 12;10(1):5683. doi: 10.1038/s41467-019-13286-z. Nat Commun. 2019. PMID: 31831742 Free PMC article.
-
The role of whole-genome sequencing for guiding systemic therapy in patients with soft tissue sarcoma.ESMO Open. 2025 Jun;10(6):105287. doi: 10.1016/j.esmoop.2025.105287. Epub 2025 Jun 11. ESMO Open. 2025. PMID: 40505420 Free PMC article.
-
Oncogenic Functions of Alternatively Spliced MDM2-ALT2 Isoform in Retroperitoneal Liposarcoma.Int J Mol Sci. 2024 Dec 17;25(24):13516. doi: 10.3390/ijms252413516. Int J Mol Sci. 2024. PMID: 39769278 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous